Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes
Revista Española de Cardiología (English Edition) · 2024
DOI: 10.1016/j.rec.2024.01.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Española de Cardiología (English Edition), 2024. Verfasst von Sergio García-Blas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain…. Hauptthemen laut MEDLINE: Quality of Life, CA-125 Antigen, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, European Regional Development Fund.
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Carbohydrate antigen 125 (CA125), a biomarker associated with fluid overload, has proven useful in managing diuretic therapy in heart failure. We aimed to evaluate the impact of diuretic optimization guided by CA125 before transcatheter aortic valve implantation (TAVI) on outcomes. METHODS: This prospective interventional study enrolled patients scheduled for TAVI, in whom baseline CA125 was measured 2 weeks before TAVI. Patients with CA125 ≥ 20 U/mL underwent diuretic up-titration before TAVI. Three groups were included: group I) baseline CA125
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovascu…
- Servicio de Cardiología, Hospital General de Castellón, Castellón, Spain.
- Servicio de Cardiología, Hospital Universitario de Torrevieja, Torrevieja, Alicante, Spain.
- Servicio de Cardiología, Hospital Francesc de Borja, Gandía, Valencia, Spain.
- Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
Förderung
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III
- European Regional Development Fund
Zitieren
APA
García-Blas, S., Pernias, V., González D'Gregorio, J., Fernández-Cisnal, A., Bonanad, C., Sastre, C., Valero, E., Miñana, G., Zaharia, G., Núñez, J., & Sanchis, J. (2024). Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2024.01.002
Vancouver
García-Blas S, Pernias V, González D'Gregorio J, Fernández-Cisnal A, Bonanad C, Sastre C, et al. Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes. Revista Española de Cardiología (English Edition). 2024. doi:10.1016/j.rec.2024.01.002
BibTeX
@article{GarcaBlas2024,
author = {García-Blas, Sergio and Pernias, Vicente and González D'Gregorio, Jessika and Fernández-Cisnal, Agustín and Bonanad, Clara and Sastre, Clara and Valero, Ernesto and Miñana, Gema and Zaharia, Georgiana and Núñez, Julio and Sanchis, Juan},
title = {Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes},
journal = {Revista Española de Cardiología (English Edition)},
year = {2024},
doi = {10.1016/j.rec.2024.01.002}
}
EUVIMED